Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
https://pharmaphorum.com/news/gilead-grabs-full-rights-to-jounce-cancer-immunotherapy/
TerryMC -
Negative about avacta from day one.
Another one for the filter!
Would those who sold during the last few weeks need to buy them back if regulations stated they had to sell ?
Really hope so..... Fingers crossed
https://thelazytrader.com/articles/learn-to-trade/most-trading-is-about-doing-nothing/
It will be amusing if there is a good RNS out in the morning....I really have no idea why people would want to sell right now.
Hold for gold !
May need to turn phone on side to view fully
Biotech M&A, is picking back up. Here are the latest deals.
Dealmaking is essential to the business of drug development. Keep track of M&A as it happens with this database.
Updated October 3, 2022
https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/
Fibroblast activation protein (FAP) is best known for its heightened expression in tumour stroma. This atypical serine protease has both dipeptidyl peptidase and endopeptidase activities, cleaving substrates at a post-proline bond. FAP expression is difficult to detect in non-diseased adult organs, but is greatly upregulated in sites of tissue remodelling, which include liver fibrosis, lung fibrosis, atherosclerosis, arthritis, tumours and embryonic tissues. Due to its restricted expression pattern and dual enzymatic activities, FAP is emerging as a unique therapeutic target. However, methods to exploit and target this protease are advancing more rapidly than knowledge of the fundamental biology of FAP. This review highlights this imbalance, emphasising the need to better define the substrate repertoire and expression patterns of FAP to elucidate its role in biological and pathological processes.
https://pubmed.ncbi.nlm.nih.gov/24470260/
Old research, but has opened my eyes to the possibility of more ailments that could be targeted.
The money would also be stretched further with additional milestone hits .....
Loving it -
The Company looks forward to providing a full technical update to shareholders on the Affimer immunotherapy and pre|CISION chemotherapy programmes as part of a Science Day event when the data sets from the pre-clinical and clinical programmes are in hand, so that the data can be presented and the development path and associated risks for the programmes can be described in detail.
Full report for anyone who's not seen it
https://www.trinitydelta.org/research-notes/fy21-results-a-year-of-frustrations-and-opportunities/
Once AVA6000 has established the clinical proof of concept, we expect increased industry interest in the pre|CISION platform. Avacta has been exploring other single-agent chemotherapies whose clinical utility would similarly benefit from improved efficacy and reduced toxicities. The most advanced is a FAP-activated proteasome inhibitor, AVA3996, a prodrug of an analogue of Takeda’s Velcade (bortezomib), which is commonly used for multiple myeloma. AVA3996 offers the prospect of reducing the dose limiting toxicities, principally peripheral neuropathy and thrombocytopenia, that constrain Velcade use to multiple myeloma and mantle cell lymphoma.
Velcade’s efficacy, particularly when used in combination regimens, could broaden its use into additional hard-to-treat indications, such as pancreatic cancers. Animal studies have shown encouraging results, with selective drug delivery to tumour sites and reduced systemic exposure. Despite approaching patent expiry in 2022 and limited clinical indications, Velcade continues to post blockbuster sales of c $1bn. Similarly, the overall protease inhibitor market is expected to post an 8.4% CAGR growth and reach $2.3bn in 2026. ***Avacta has earmarked funds from the June 2020 raise to complete the preclinical package *** and is on track to start the first-in-human Phase I clinical trial in H223.
yngladbuys - sit on your shares as long as you can and hopefully we will get an RNS that locks everyone in/out and a slice of this company gets taken/bought for a very large amount.
Treated myself to a few more....
At these crazy prices it has given long term shareholders a chance to fill their boots .
Not long to wait for the almost inevitable!
Partial excerpt:-
An online resource that logs side effects in cancer patients to help assess their quality of life will benefit from a new framework, thanks to researchers.
The European Organisation for Research and Treatment of Cancer (EORTC) has an Item Library that offers coverage of side effects – also called adverse events, AEs - important to cancer patients and the impact they have on their quality of life and emotional wellbeing.
Researchers from the University of Leeds’ School of Medicine and the EORTC have now created a new framework to systematically classify and improve searchability and item selection for relevant AEs in the Item Library after clinicians, researchers and regulatory authorities highlighted an increasing need for a patient-centred approach in measuring AEs and their burden on patients.
The framework developed by study, published in the Journal of Clinical Oncology, will now be integrated into the Item Library’s online searchable database.
Gold standard for side effects reporting
The gold standard for the classification of side effects reporting in cancer clinical trials is the Common Terminology Criteria for Adverse Events (CTCAE). Used by clinicians, it includes more than 835 different side effects, including using laboratory and imaging findings.
Patient-reported outcomes (PROs) complement clinician reporting by directly capturing the patient perspective. The EORTC Item Library supplements the standard PRO questionnaires and modules developed by the EORTC QLG to assess quality of life for cancer patients. The Item Library allows for more flexibility through customised lists of questions (item lists) that can be used to better cover new disease and treatment contexts.
It covers symptoms and treatment-related burden, emotional functioning and overall quality of life.
https://medicinehealth.leeds.ac.uk/faculty-/news/article/573/new-framework-for-cancer-patient-side-effects-to-help-assess-quality-of-life
The pharmaceutical industry has sustained momentum since the vaccine bounce - are they a recession-proof investment?
The pandemic shone a spotlight on the pharmaceutical and biotech industry and their share prices hit new highs as a result.
Big pharmaceutical players have continued to perform well into 2022 even as other sectors flounder in the face of the cost of living crisis and rising inflation.
Broad exposure to the sector means investors can capitalise on the increased long-term demand for healthcare solutions.
The pharmaceutical industry has undergone significant change over the past few years.
While the Covid vaccines made headlines, years of research are starting to bear fruit for big players like AstraZeneca and GlaxoSmithKline.
But with a recession looming will pharmaceutical players be able to sustain their momentum? And could it be a good time to invest in biotech firms, which have seen their shares languish?
The Covid vaccine has raised AstraZeneca's global profile significantly and in February it reported a record quarter for revenues including $1.8billion from the Covid vaccine and sales from its $39billion acquisition of Alexion. It also increased its dividend for the first time in a decade.
AstraZeneca is now the second largest FTSE 100 company by market cap after doubling its share price in five years and is a popular holding among income funds including Artemis and Columbia Threadneedle UK Equity Income fund.
'Big pharma as represented by FTSE 100 constituents AstraZeneca and GlaxoSmithKline have performed well in the wider market slump this year. Their shares are up 28 per cent and 8 per cent, respectively, in the year-to-date,' says Garry White, Charles Stanley's chief investment commentator.
'Covid-19 related sales are slowly unwinding, but the loosening of pandemic restrictions have boosted sales of other vaccines, sales of cancer drugs have been rising - and the major players have good pipelines of potential new products in development.'
https://www.thisismoney.co.uk/money/investing/article-11024301/Is-good-time-invest-pharmaceutical-biotech-stocks.html?
ico=mol_mobile_moneyinvesting-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Finvesting%2Findex.html
5. Conclusions
Affimer reagents have been shown during this project to be able to bind to VIM-1, and in preliminary
experiments show inhibitory effects on its rate of hydrolysis of nitrocefin. The modification of a
target protein by inclusion of a biotin acceptor peptide tag has also been demonstrated to be a
useful technique to assist in screening, though further investigation may be needed on resultant
orientation of a BAP-tagged protein when bound to streptavidin.
Future work needs to be done to characterise the type of inhibition witnessed during these results,
as well as a given Affimers ability to inhibit VIM-1 in vivo. When coupled with prior work on NDM-1,
these are good steps towards verifying Affimers as desperately needed inhibitors of metallo-ß?lactamases in the ongoing struggle against antibiotic resistant pathogens. The rapid screening of
Affimer libraries against a target alongside their low cost and ease of manufacturing make Affimers
useful tools for the future
.....told yer it was a lot to take in ..
4.4. Continuation of the Project and Future Applications
Affimer61 was shown to bind to VIM-1 and successfully modulate its activity in an n=3 series of
experiments. Further work is required to establish an IC50 of this Affimer as well as its effectiveness
against VIM-1 expressing bacteria in vivo, and a crystal structure of VIM-1 with Affimer bound would
help to elucidate its method of inhibition, and possible application to other VIM-variants.
Work to express VIM-1 variants and test Affimer cross reactivity is also necessary, as there is a great
need for cross-reactive metallo beta lactamase inhibitors. Further phage display screening could also
be used to select cross-reactive Affimer binders in the hope of isolating a broad range inhibitor.
4.4.1. Ongoing work using reagents created in this project
Since the conclusion of research on this project, L. Medinger (University of Leeds) has continued
testing for Affimer reagent inhibitors of VIM-1. Using the purified phage from the second round of
phage display and stocks of BAP-tagged VIM-1 created during this project he has performed the
third pan of phage display and phage ELISA to try and identify unique Affimers that target VIM-1.
In early tests, one such Affimer appears to have an inhibitory effect on VIM-1 at 33-fold
concentration (50 nM VIM-1, 1.5 µM Affimer14)